A rare case of multiple bladder hemangiomas associated with Glanzmann thrombasthenia: Successful control of refractory hematuria by super selective vesical artery embolization Authors: Ahmed Chaabouni, Mahmoud Ghozzia, Wafa Elleuch, Kays Chaker, Yassine Nouira, Mourad Hadj Slimen Published: 2026 ABSTRACT AbstractBladder hemangiomas are rare benign vascular tumors that may cause severe hematuria. We report a 66-year-old man with Glanzmann thrombasthenia who presented with life-threatening hematuria, clot retention, and severe anemia. Histopathological examination revealed multiple capillary bladder hemangiomas, while contrast-enhanced CT failed to clearly identify the lesions due to their small size. Despite intensive hematological support, including transfusions, recombinant activated factor VII, and transurethral electrocoagulation, bleeding recurred. Given the prohibitive hemorrhagic risk of repeat surgery, super selective vesical artery embolization was performed, achieving complete and durable hemostasis. No complications or recurrence occurred during six months of follow-up.Keywords: Bladder hemangioma, Glanzmann thrombasthenia, Hematuria, Vesical, Artery embolization Introduction Bladder hemangioma is a rare benign vascular tumor accounting for approximately 0.6% of all bladder neoplasms.1 Histologically, it can be classified as capillary, cavernous, or arteriovenous, with the cavernous subtype being the most common form.1 Despite its benign nature, bladder hemangioma frequently presents with gross hematuria, which can occasionally be severe and recurrent. Owing to its highly vascular characteristics, diagnostic and therapeutic endoscopic interventions may be associated with a substantial risk of bleeding.2 Given the rarity of this condition, no standardized treatment guidelines currently exist. Management is therefore individualized and largely determined by lesion size, multiplicity, location, and depth of bladder wall involvement. Reported therapeutic options range from conservative surveillance and transurethral fulguration to laser therapy, partial cystectomy, and selective arterial embolization.3 Glanzmann thrombasthenia is a rare inherited platelet function disorder caused by quantitative or qualitative abnormalities of the platelet glycoprotein IIb/IIIa receptor complex. The resulting defect in platelet aggregation leads to a lifelong predisposition to mucocutaneous and surgical bleeding.4 Consequently, conventional urological procedures, including bladder biopsy, transurethral resection, and major surgery, may carry a particularly high risk of severe or uncontrollable hemorrhage in affected patients. Herein, we report the case of a 66-year-old patient with Glanzmann thrombasthenia who presented with life-threatening persistent gross hematuria secondary to multiple bladder hemangiomas. Following unsuccessful endoscopic management, durable hemostasis was achieved through super-selective embolization of the vesical arteries. To our knowledge, the coexistence of multiple bladder hemangiomas and Glanzmann thrombasthenia has rarely been reported, making both diagnosis and treatment especially challenging. Case presentation A 66-year-old man with a known diagnosis of Glanzmann thrombasthenia and a history of localized prostate adenocarcinoma successfully treated with combined radiotherapy and androgen deprivation therapy, without evidence of biochemical recurrence, presented to the emergency department with gross hematuria associated with clot retention and significant blood loss. The patient reported having undergone cystoscopy and bladder biopsy a few weeks earlier as part of the initial evaluation of hematuria. Notably, he stated that this episode represented his first occurrence of hematuria and that the bleeding had worsened considerably after the endoscopic procedure. Histopathological examination of the biopsy specimens revealed capillary bladder hemangiomas, with no evidence of urothelial carcinoma, sarcoma, or melanoma (Fig. 1). Numerous thin walled and blood-filled vessels of the bladder hemangioma (HE x 50). Upon admission to our department, the patient required multiple transfusions of leukocyte-depleted packed red blood cells and platelet concentrates. Hemostatic support was provided with intravenous recombinant activated factor VII (rFVIIa) administered in accordance with hematological recommendations. A contrast-enhanced CT scan was performed; however, it failed to clearly demonstrate the bladder hemangiomas because of the small size of the lesions. However, persistent gross hematuria necessitated surgical intervention. Under comprehensive hematological coverage, transurethral electrocoagulation of the bleeding lesions was performed. Cystoscopic examination demonstrated multiple hyperemic sessile and polypoid lesions involving the posterior and right lateral walls of the bladder, findings consistent with the previously established diagnosis of bladder hemangiomas (Fig. 2). Endoscopic view demonstrating hyperemic (A) and polypoid bladder wall lesions, consistent with bladder hemangioma (B). Following the procedure, hematuria gradually improved. Eight days later, the urine became progressively clear, and the patient was discharged with a stabilized hemoglobin level of 10.4 g/dL. Twelve days after discharge, he was urgently readmitted with recurrent severe macroscopic hematuria and acute urinary retention secondary to massive clot formation. Laboratory investigations revealed a hemoglobin level of 6.8 g/dL. Continuous bladder irrigation was initiated, and clot evacuation was performed. Despite intensive supportive treatment, including platelet transfusions and repeated administration of rFVIIa, bleeding persisted. Given the failure of endoscopic electrocoagulation, the recurrence of severe hematuria, and the prohibitive hemorrhagic risk associated with repeat transurethral surgery or partial cystectomy in the setting of Glanzmann thrombasthenia, the case was discussed during a multidisciplinary meeting involving urologists, hematologists, and interventional radiologists. A decision was made to proceed with super selective arterial embolization as a minimally invasive strategy to achieve definitive hemostasis. Pelvic angiography demonstrated hypertrophied vesical branches arising from the anterior division of the right internal iliac artery, supplying a marked hypervascular blush within the posterolateral bladder wall corresponding to the lesions previously identified on cystoscopy. Super-selective catheterization of the pathological feeding vessels was successfully achieved using a microcatheter (Fig. 3). The procedure was completed without complications. Post-embolization angiography confirmed complete devascularization of the target lesions. Angiography revealed a marked hypervascular blush involving the posterolateral bladder wall (A). Superselective catheterization of the pathological feeding vessels was successfully performed using a microcatheter (B). Within 24 hours of embolization, the urine changed from grossly hemorrhagic to light pink. Complete resolution of hematuria was observed within 72 hours, with restoration of clear urine. The patient remained hemodynamically stable throughout the postoperative period and was discharged on the fourth day after the procedure. At six months of follow-up, he remained asymptomatic, with no recurrence of hematuria and no embolization-related complications. Discussion Bladder hemangioma is an exceptionally rare benign vascular lesion, accounting for approximately 0.6% of all bladder tumors and occurring predominantly in males younger than 30 years of age.1 The most common clinical manifestation is recurrent gross hematuria, which may range from intermittent bleeding to severe hemorrhage associated with clot retention and significant anemia.3 Bladder hemangiomas may occur as isolated lesions or in association with systemic vascular malformations. Their coexistence with cutaneous hemangiomas has been described, and they have occasionally been reported in patients with Sturge-Weber syndrome or Klippel-Trenaunay-Weber syndrome.5 Cystoscopically, bladder hemangiomas are usually solitary lesions measuring less than 3 cm in diameter and are most commonly located at the bladder dome, posterior wall, or trigone. The presence of a bluish, sessile, highly vascular mass in a patient presenting with gross hematuria is highly suggestive of the diagnosis.5 In contrast, our patient presented with multiple diffuse lesions involving the posterior and lateral bladder walls, a less common presentation that further complicated management. The etiology of bladder hemangiomas remains poorly understood, and no clearly established risk factors have been identified. However, Hu and Deng suggested that radiation-induced vascular injury, which has been implicated in the development of angiosarcomas, may also contribute to the formation of benign vascular lesions such as hemangiomas.6 In this context, our patient's previous pelvic radiotherapy for prostate cancer may have played a role in the development of his bladder lesions, although a causal relationship cannot be established. Because of the rarity of this condition, no standardized treatment strategy currently exists. For small and superficial lesions, biopsy combined with fulguration is often considered an effective first-line approach. Other endoscopic techniques, including transurethral resection, electrocoagulation, and Nd:YAG laser photocoagulation, have also shown satisfactory results.1,3 However, manipulation of large or highly vascular hemangiomas may result in severe hemorrhage. Notably, a fatal case of uncontrolled bleeding following transurethral resection of a bladder hemangioma has been reported in the literature.3 For extensive, multifocal, or deeply infiltrating lesions, and in cases where conservative measures fail, partial or radical cystectomy has traditionally been considered the most definitive therapeutic option.1,3 In our patient, however, the coexistence of multiple diffuse bladder hemangiomas and Glanzmann thrombasthenia considerably limited the available treatment options. Complete endoscopic control was unlikely to be durable, while major surgical intervention carried an unacceptably high risk of perioperative hemorrhage. Consequently, selective arterial embolization emerged as an attractive minimally invasive alternative. Although the evidence supporting its use in bladder hemangiomas is limited to case reports and small series, the available literature suggests that embolization can provide effective and durable bleeding control in carefully selected patients. Safar et al. described a patient with a large bladder hemangioma successfully treated with angioembolization and reported excellent long-term outcomes.7 Although recurrence occurred five years later because of vascular recanalization, repeat embolization resulted in complete symptom resolution, emphasizing both the effectiveness and repeatability of the technique.7 Similarly, Lim et al. reported successful control of massive hematuria secondary to bladder hemangioma using selective arterial embolization.8 The rationale for embolization is based on occlusion of the arterial feeders supplying the lesion, resulting in devascularization without direct manipulation of the fragile vascular mucosa. This approach minimizes the risk of catastrophic bleeding associated with transurethral resection or repeated biopsy procedures. To further reduce the risk of ischemic complications, including bladder necrosis, prostate injury, or non-target embolization, a super-selective approach targeting only the pathological vesical branches is preferred. Most severe complications reported in the literature have been associated with less selective embolization of the internal iliac artery rather than super-selective vesical artery embolization.3 Evidence supporting the efficacy of this approach continues to grow. Tsitskari et al. reported a long-term clinical success rate of approximately 85% following super-selective embolization of the vesical arteries for intractable bladder hemorrhage.9 Likewise, the systematic review by Taha et al. concluded that selective vesical artery embolization is a safe and effective salvage treatment for refractory hematuria when conservative measures fail.10 An additional challenge in our case was the peri-procedural management of Glanzmann thrombasthenia. Successful treatment required close collaboration between urologists, hematologists, and interventional radiologists. Platelet transfusion, preferably using HLA-matched platelet concentrates when available, remains the cornerstone of hemostatic management in patients with severe bleeding episodes.4,11,12 Recombinant activated factor VII served as a critical adjunctive therapy by enhancing thrombin generation and partially bypassing the platelet aggregation defect. Current recommendations support administration of rFVIIa at a dose of 90 μg/kg every 2 hours until adequate hemostasis is achieved.4,12 In the present case, the combination of intensive hematological support and super-selective vesical artery embolization resulted in rapid cessation of hematuria, avoidance of major surgery, and sustained symptom-free follow-up at six months. This experience suggests that embolization should be considered among the therapeutic options for refractory bladder hemangioma-associated hemorrhage, particularly in patients with severe inherited bleeding disorders for whom conventional surgical approaches carry prohibitive risks. Conclusion This case demonstrates that super selective vesical artery embolization can be a safe, effective, and bladder-preserving treatment option for refractory hematuria caused by bladder hemangiomas in patients with severe hemorrhagic disorders such as Glanzmann thrombasthenia. In situations where conventional endoscopic management fails and surgical intervention carries prohibitive bleeding risks, embolization should be considered as a valuable therapeutic alternative. Careful multidisciplinary management and long-term follow-up are essential to optimize outcomes and detect disease recurrence. CRediT authorship contribution statement Ahmed Chaabouni: Writing – original draft, Validation. Mahmoud Ghozzia: Writing – original draft, Validation. Wafa Elleuch: Writing – original draft, Validation. Kays Chaker: Investigation, Conceptualization. Yassine Nouira: Investigation, Conceptualization. Mourad Hadj Slimen: Validation, Investigation. Consent for publication An informed consent was obtained from the patient to use the necessary data for publication. Availability of data and materials The data used and/or analysed during the current study are available from the corresponding author on reasonable request. Clinical trial number Not applicable. Ethics approval and consent to participate An informed consent was obtained from the patient. Funding The authors declare that they have no funding sources. Competing interests The authors declare that they have no competing interests. References Associated Data Data Availability Statement The data used and/or analysed during the current study are available from the corresponding author on reasonable request.